Trademark Overview
On Monday, October 7, 2024, a trademark application was filed for MAXION with the United States Patent and Trademark Office. The USPTO has given the MAXION trademark a serial number of 79412149. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, October 22, 2025. This trademark is owned by Maxion Therapeutics Limited. The MAXION trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and GPCR activity, in particular, preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel and GPCR activity, in particular, those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; antibodies for medical use; pharmaceuticals and drugs in the nature of pharmaceutical preparations incorporating antibodies, ion channel modulating and GPCR modulating antibodies or antibodies derived from mini-protein toxins for the treatment of diseases and conditions associated with dysregulation of ion channel and GPCR activity, in particular, those for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; human ...
Medical services; medical diagnostic testing, analysis and diagnostic services for the treatment of patients in the field of antibodies; medical services for the treatment of diseases through the use of antibodies, ion channel modulating and GPCR modulating antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Scientific and technological services and research and design relating thereto, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating and GPCR modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; medical and scientific laboratory services relating to the production of antibodies, ion channel modulating and GPCR modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
Biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating and GPCR modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating and GPCR modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
